Table 5.

Safety outcomes by prophylaxis decision

	Under	Correct	Over	p
Clinical Events (patient level, n = 1447)
Bone pain	23.6%	28.5%	25.0%	n.s.
Thrombocytopenia	19.4%	17.4%	17.7%	n.s.
Serum LDH increase	16.6%	20.2%	14.4%	n.s.
Muscle pain	12.1%	16.8%	16.1%	n.s.
Joint pain	11.6%	15.9%	15.6%	n.s.
Serum GGT increase	12.8%	14.9%	15.4%	n.s.
Serum ALP increase	11.9%	13.3%	15.3%	n.s.
Other neurological symptoms	8.7%	7.5%	7.4%	n.s.
Headache	3.4%	8.9%	7.3%	0.027
Blood uric acid increase	9.3%	7.7%	5.0%	n.s.
Confusion/altered mental status	3.5%	2.6%	4.6%	n.s.
Epistaxis	1.8%	2.2%	2.5%	n.s.
Bleeding other than GI, skin hemorrhage	2.6%	2.0%	2.8%	n.s.
Splenomegaly	1.3%	1.2%	0.3%	n.s.
GI bleeding	0.4%	0.9%	0.3%	n.s.
Skin hemorrhage	0.4%	0.8%	0.3%	n.s.
Adverse drug reactions (cycle-level, n = 6142)	2.3%	1.8%	1.5%	n.s.

ALP alkaline phosphatase, GGT gamma glutamyl transpeptidase, GI gastro intestinal, LDH lactate dehydrogenase n.s. not significant